Selma Mesen

Dr. Selma Mesen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
AMAli Mesen
Ali Mesen
SMSelma Mesen
Selma Mesen
ABAbdullah Beyoglu
Abdullah Beyoglu
YIYılmaz Inanc
Yılmaz Inanc

1 June 2020 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
MOMuhammet Derda Ozer
Muhammet Derda Ozer
MBMuhammed Batur
Muhammed Batur
SMSelma Mesen
Selma Mesen
STSerek Tekin
Serek Tekin
ESErbil Seven
Erbil Seven
TYTekin Yasar
Tekin Yasar

5 February 2024 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
SMSelma Mesen
Selma Mesen
MOMuhammet D Ozer
Muhammet D Ozer
MBMuhammed Batur
Muhammed Batur
Purpose: This study was planned to compare the clinical results and optical coherence tomography (OCT) data of patients who underwent adalimumab (ADA), infliximab (IFX) and switched protocols between these two methods in cases of Behçet’s associated uveitis (BAU). Methods: The patients with BAU who were treated with anti-TNF- α agents for at least one year were qualified for the chart review. The outcome parameters were the steroid-free remission state, the best-corrected visual acuity (BCVA), the central macular thickness (CMT), and the subfoveal choroidal thickness (SFCT) of the patients at the last visit. Results: After a mean follow-up of 16.60 months, the rate of active inflammation decreased from 63.6% to 15.1%. Mean BCVA increased, mean CMT and mean SFCT decreased significantly at the last visit ( P < 0.001, P < 0.001, respectively). Conclusion: Anti-TNF- α treatment and switching protocols between these two agents effectively and safely control intraocular inflammation in BAU patients.

28 June 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
AMAli Mesen
Ali Mesen
SMSelma Mesen
Selma Mesen
FOFurkan Oz
Furkan Oz
ABAbdullah Beyoglu
Abdullah Beyoglu

20 May 2024 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
AMAli Mesen
Ali Mesen
CTCelaleddin Turgut
Celaleddin Turgut
SMSelma Mesen
Selma Mesen
ABAbdullah Beyoğlu
Abdullah Beyoğlu
Purpose: To evaluate the optical coherence tomography-angiography (OCT-A) findings and choroidal vascularity index (CVI) of patients followed with a diagnosis of obsessive-compulsive disorder (OCD) by comparing them with the healthy control group (HCG). Methods: This prospective study included 33 patients diagnosed with OCD and 32 HCG patients who followed up for at least 3 months. OCT-A images were obtained to evaluate the microvascular circulation, and enhanced HD line images were obtained for the CVI calculation of all patients. Results: Statistical analysis results revealed that the rates of superficial vascular density in the fovea region and deep vascular density in the parafovea region decreased in the OCD group compared to the HCG group ( P = 0.003 and P = 0.010, respectively). Subfoveal choroidal thickness values of the OCD group were lower than those of the HCG group ( P = 0.008). While total choroidal area and lumen area values were lower in the OCD group than in the HCG group ( P < 0.001 and P < 0.001, respectively); CVI values were similar in both groups ( P = 0.436). Conclusion: The use of the OCT-A device, which is a non-invasive method for detecting retinal and choroidal changes in OCD cases, may provide insight into the pathogenesis of the disease.

23 September 2024 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
SMSelma Mesen
Selma Mesen
ACAysegul Comez
Aysegul Comez
AMAli Mesen
Ali Mesen
ABAbdullah Beyoğlu
Abdullah Beyoğlu
MSMuhammed Seyithanoğlu
Muhammed Seyithanoğlu
Objectives: Comparing serum and humor aqueous (HA) raftlin levels in diabetic patients and control group. Methods: In this prospective study, patients were divided into two groups diabetes mellitus (DM) and a control group. The DM group was divided into three subgroups. A total of 160 patients, including 35 without diabetic retinopathy (non-DR) (Group 1), 31 non-proliferative diabetic retinopathy (NPDR) (Group 2), 32 proliferative diabetic retinopathy (PDR) (Group 3), and 62 controls (Group 4), were included in the study. Venous blood and HA samples were taken from the patients and their raftlin levels were measured. Results: Serum raftlin levels were decreased in the DM main group (p=0.046) but there was no significant difference in HA raftlin levels (p=0.838). There was no significant difference between the subgroups (Groups 1, 2, 3, and 4) in terms of serum and HA raftlin levels. Diabetic macular edema (DME), anti-vascular endothelial growth factor (anti-VEGF), and panretinal photocoagulation (PRP) application were not found to be associated with raftlin levels in Group 3. A moderate positive correlation was found between serum and HA raftlin levels (r=0.491). There was a negative correlation between serum raftlin levels and serum glucose levels (p=0.05). No correlation was found between serum and HA raftlin levels and serum leukocyte and lipid levels (p>0.05). Conclusions: In our study, raftlin levels were examined for the first time in DM patients and it was observed that serum raftlin levels were negatively correlated with glucose levels. Raftlin molecule may be involved in the etiology of DM through VEGF.